In vivo delivery of interleukin-4 by a recombinant vaccinia virus prevents tumor development in mice.
To study the immunotherapeutic potential of interleukin-4 (IL-4) delivered in vivo via a recombinant vaccinia virus, a thymidine kinase-negative (TK-) vaccinia virus that expressed the murine IL-4 gene (VV1/IL-4) was constructed. When mice were inoculated with 10(7) plaque-forming units (pfu) of VV1/IL-4 subcutaneously (s.c.), 10(5) pfu/cm2 were found in skin, and smaller numbers in liver and kidney between 1 and 7 days after infection; few viral pfu were found in spleen and lung, or in any organ after intravenous infection. This suggested that recombinant vaccinia viruses might be most efficient at delivery of cytokine genes to the skin. Because IL-4 has recently been found to have potent anti-tumor activity, the effect of recombinant virus infection on the development of s.c. tumors was studied. A single s.c. inoculation with VV1/IL-4 delayed the development of NCTC 2472 tumors, but when VV1/IL-4 was inoculated s.c. weekly for 8 weeks, tumor development was completely prevented in 93% of mice. Similarly, the development of M-3 melanoma tumors was also prevented by weekly s.c. inoculations of VV1/IL-4. About 40% of mice treated with control VV2/beta gal by the same regimen also failed to develop tumors. Weekly virus treatment did not prevent NCTC 2472 tumor development in athymic nu/nu mice, suggesting that mature T cells are required for expression of VV1/IL-4 induced antitumor activity. Thus, recombinant vaccinia viruses may be especially well suited for convenient therapeutic delivery of immunomodulator genes to skin-related sites.
Elkins
K L
KL
Laboratory of Enteric and Sexually Transmitted Diseases, DBP, CBER, FDA, Bethesda, MD 20852.
Ennist
D L
DL
Winegar
R K
RK
Weir
J P
JP
D000818:Animals; D001202:Ascitic Fluid / Q000821:virology; D005822:Genetic Vectors; D015847:Interleukin-4 / Q000008:administration & dosage*; D008297:Male; D008546:Melanoma, Experimental / Q000517:prevention & control; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008811:Mice, Inbred DBA; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000517:prevention & control*; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage*; D012867:Skin / Q000821:virology; D013937:Thymidine Kinase / Q000172:deficiency; D014018:Tissue Distribution; D014616:Vaccinia virus / Q000235:genetics / Q000302:isolation & purification / Q000502:physiology; D014764:Viral Proteins; D014779:Virus Replication; D014781:Viscera / Q000821:virology
D011993:Recombinant Fusion Proteins; D014764:Viral Proteins; D015847:Interleukin-4; D013937:Thymidine Kinase